Annexon, Inc. (NASDAQ:ANNX) Receives $15.80 Average Price Target from Brokerages

Shares of Annexon, Inc. (NASDAQ:ANNX) have earned a consensus recommendation of “Buy” from the six research firms that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $15.80.

A number of equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Annexon in a research note on Tuesday, December 17th. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Annexon in a research report on Tuesday, March 4th.

Annexon Stock Performance

NASDAQ:ANNX opened at $2.50 on Thursday. The company has a market cap of $274.28 million, a PE ratio of -2.38 and a beta of 1.14. The company has a 50 day simple moving average of $3.34 and a two-hundred day simple moving average of $5.15. Annexon has a 12 month low of $2.30 and a 12 month high of $8.40.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Research analysts forecast that Annexon will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Annexon

Several large investors have recently added to or reduced their stakes in the company. Parkman Healthcare Partners LLC raised its position in shares of Annexon by 0.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock valued at $1,945,000 after purchasing an additional 1,768 shares during the period. The Manufacturers Life Insurance Company increased its stake in Annexon by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock worth $945,000 after buying an additional 2,450 shares in the last quarter. GSA Capital Partners LLP raised its holdings in Annexon by 10.7% during the third quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after acquiring an additional 3,355 shares during the period. E Fund Management Co. Ltd. boosted its stake in shares of Annexon by 36.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Annexon by 6.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock worth $325,000 after purchasing an additional 4,092 shares in the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.